UK markets closed

Hyloris Pharmaceuticals SA (52U.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
11.55-0.10 (-0.86%)
As of 08:16AM CEST. Market open.
Full screen
Previous close11.65
Open11.55
Bid11.45 x N/A
Ask11.95 x N/A
Day's range11.55 - 11.55
52-week range10.60 - 13.35
Volume80
Avg. volume11
Market cap328.957M
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters

    Hyloris Pharma wins US FDA approval for pain treatment

    The U.S. health regulator has approved Hyloris Pharmaceuticals' drug for post-operative pain, the Belgium-based company said on Wednesday, adding that it expects to launch the non-opioid treatment in the United States by early next year. The injectable drug, branded as Maxigesic IV, was approved as a post-operative drug in hospitals or when patients cannot take medicine orally. Maxigesic IV, a combination of paracetamol with ibuprofen solution for infusion, helps reduce pain and inflammation without the risk of opioid addiction that resulted in more than half a million deaths in the U.S. during 1999 to 2020.